Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05478993 | Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement(SPODUMENE) | unknown | Phase 2 | 21 | Peking University People's HospitalOTHER | 1 | Jan 31, 2024 |
| clinicaltrials |
| NCT06223646 | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 29 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy | terminated | Phase 2 | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01190787 | Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone | completed | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 9 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03506360 | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03915184 | Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | active not recruiting | Phase 1 / Phase 2 | 105 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT04682405 | Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) | completed | Phase 2 | 51 | Washington University School of MedicineOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT01913730 | Maintenance Therapy With Subcutaneous Bortezomib | completed | Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant(ASCENT) | active not recruiting | Phase 2 | 87 | International Myeloma FoundationOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | unknown | Phase 2 | 50 | Chunyan Sun, MDOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02843074 | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT02834364 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)(GMMG-BIRMA) | completed | Phase 2 | 12 | University of Heidelberg Medical CenterOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03224507 | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma(MASTER) | completed | Phase 2 | 123 | University of Alabama at BirminghamOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | withdrawn | Phase 1 / Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | withdrawn | Phase 1 / Phase 2 | 0 | LaNova Medicines LimitedINDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.(PENTI-MIDAS) | withdrawn | Phase 2 | 0 | Nantes University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06132711 | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05998928 | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy | unknown | Phase 2 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT00734149 | Bortezomib With Melphalan and Prednisone for Multiple Myeloma(MVP) | completed | Phase 2 | 45 | Duke UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | terminated | Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM(HO147SMM) | active not recruiting | Phase 2 | 58 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Nov 1, 2023 | clinicaltrials |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02547662 | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT00777998 | Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma | completed | Phase 2 | 221 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | terminated | Phase 2 | 19 | OncotherapeuticsINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients(ClaSPd) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd) | active not recruiting | Phase 1 / Phase 2 | 66 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02308280 | Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients | completed | Phase 2 | 40 | Maisonneuve-Rosemont HospitalOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04558931 | Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | recruiting | Phase 2 | 62 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02509052 | Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | terminated | Phase 1 / Phase 2 | 32 | Sherif Farag, MB, BSOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02685826 | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 56 | CelgeneINDUSTRY | 8 | Oct 6, 2023 | clinicaltrials |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Srinivas DevarakondaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03155100 | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines(KEd) | completed | Phase 2 | 15 | Raija SilvennoinenOTHER | 2 | Sep 26, 2023 | clinicaltrials |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 31, 2024source: clinicaltrials